D
Corvus Pharmaceuticals, Inc.
CRVS
$4.50
-$0.13-2.81%
D
Sell
12/20/2024Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 12/20/2024 due to an increase in the total return index and valuation index.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 12/20/2024 due to an increase in the total return index and valuation index.
E
Sell
11/29/2024Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 11/29/2024 due to a major decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.0714 to -$0.6029, debt to equity increased from 0.01 to 0.03, and the quick ratio declined from 3.55 to 0.9.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 11/29/2024 due to a major decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.0714 to -$0.6029, debt to equity increased from 0.01 to 0.03, and the quick ratio declined from 3.55 to 0.9.
D
Sell
9/12/2024Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 9/12/2024 due to an increase in the total return index and volatility index.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 9/12/2024 due to an increase in the total return index and volatility index.
E
Sell
8/28/2024Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 8/28/2024 due to a decline in the valuation index.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 8/28/2024 due to a decline in the valuation index.
D
Sell
5/15/2023Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 5/15/2023 due to an increase in the volatility index and total return index.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 5/15/2023 due to an increase in the volatility index and total return index.
E
Sell
5/9/2023Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 5/9/2023 due to a decline in the volatility index.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 5/9/2023 due to a decline in the volatility index.
D
Sell
4/24/2023Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 4/24/2023 due to a large increase in the growth index, volatility index and total return index. EBIT increased 55.23% from -$12.33M to -$5.52M, and earnings per share increased from -$0.3186 to -$0.2109.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 4/24/2023 due to a large increase in the growth index, volatility index and total return index. EBIT increased 55.23% from -$12.33M to -$5.52M, and earnings per share increased from -$0.3186 to -$0.2109.
E
Sell
3/14/2023Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/23/2023Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.01 to 0.02, EBIT declined 79.5% from -$6.87M to -$12.33M, and earnings per share declined from -$0.1796 to -$0.3186.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.01 to 0.02, EBIT declined 79.5% from -$6.87M to -$12.33M, and earnings per share declined from -$0.1796 to -$0.3186.
D
Sell
10/28/2022Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 10/28/2022 due to a decline in the volatility index.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 10/28/2022 due to a decline in the volatility index.
D
Sell
10/13/2022Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 10/13/2022 due to an increase in the growth index and volatility index. EBIT increased 5.5% from -$7.27M to -$6.87M, and operating cash flow increased 4.69% from -$6.42M to -$6.12M.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 10/13/2022 due to an increase in the growth index and volatility index. EBIT increased 5.5% from -$7.27M to -$6.87M, and operating cash flow increased 4.69% from -$6.42M to -$6.12M.
D
Sell
5/31/2022Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 05/31/2022.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 05/31/2022.
E
Sell
5/13/2022Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 5/13/2022 due to a decline in the growth index, total return index and volatility index. EBIT declined 10.52% from -$6.58M to -$7.27M.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E+ from D- on 5/13/2022 due to a decline in the growth index, total return index and volatility index. EBIT declined 10.52% from -$6.58M to -$7.27M.
D
Sell
3/31/2022Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 3/31/2022 due to a substantial decline in the valuation index, growth index and total return index.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 3/31/2022 due to a substantial decline in the valuation index, growth index and total return index.
D
Sell
1/13/2022Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D from D+ on 1/13/2022 due to a large decline in the total return index.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D from D+ on 1/13/2022 due to a large decline in the total return index.
D
Sell
11/15/2021Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D+ from D- on 11/15/2021 due to an increase in the valuation index, total return index and solvency index. The quick ratio increased from 5.38 to 6.78.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D+ from D- on 11/15/2021 due to an increase in the valuation index, total return index and solvency index. The quick ratio increased from 5.38 to 6.78.
D
Sell
11/8/2021Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 11/08/2021.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 11/08/2021.
D
Sell
8/3/2021Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 8/3/2021 due to a large increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.3355 to -$0.28, the quick ratio increased from 4.89 to 5.38, and EBIT increased 1.68% from -$11.48M to -$11.29M.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 8/3/2021 due to a large increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.3355 to -$0.28, the quick ratio increased from 4.89 to 5.38, and EBIT increased 1.68% from -$11.48M to -$11.29M.
D
Sell
5/19/2021Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 5/19/2021 due to a noticeable decline in the growth index, valuation index and volatility index. Earnings per share declined from $0.9247 to -$0.34, EBIT declined 16.24% from -$9.88M to -$11.48M, and operating cash flow declined 7.07% from -$8.21M to -$8.79M.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 5/19/2021 due to a noticeable decline in the growth index, valuation index and volatility index. Earnings per share declined from $0.9247 to -$0.34, EBIT declined 16.24% from -$9.88M to -$11.48M, and operating cash flow declined 7.07% from -$8.21M to -$8.79M.
D
Sell
7/31/2020Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 7/31/2020 due to an increase in the total return index, volatility index and growth index. EBIT increased 18.86% from -$13.27M to -$10.77M, and earnings per share increased from -$0.4398 to -$0.3606.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 7/31/2020 due to an increase in the total return index, volatility index and growth index. EBIT increased 18.86% from -$13.27M to -$10.77M, and earnings per share increased from -$0.4398 to -$0.3606.
D
Sell
3/12/2019Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 3/12/2019 due to a noticeable decline in the total return index, volatility index and growth index. EBIT declined 0.2% from -$11.15M to -$11.17M.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 3/12/2019 due to a noticeable decline in the total return index, volatility index and growth index. EBIT declined 0.2% from -$11.15M to -$11.17M.
D
Sell
8/3/2018Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 8/3/2018 due to a major increase in the growth index. Earnings per share increased from -$0.6333 to -$0.4014, EBIT increased 16.29% from -$14.64M to -$12.26M, and operating cash flow increased 1.41% from -$11.05M to -$10.89M.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 8/3/2018 due to a major increase in the growth index. Earnings per share increased from -$0.6333 to -$0.4014, EBIT increased 16.29% from -$14.64M to -$12.26M, and operating cash flow increased 1.41% from -$11.05M to -$10.89M.
D
Sell
7/27/2018Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 7/27/2018 due to a decline in the total return index and volatility index.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 7/27/2018 due to a decline in the total return index and volatility index.
D
Sell
7/6/2018Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 7/6/2018 due to an increase in the solvency index, efficiency index and total return index. Total capital increased 61.76% from $84.84M to $137.23M, and the quick ratio increased from 10.06 to 13.59.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 7/6/2018 due to an increase in the solvency index, efficiency index and total return index. Total capital increased 61.76% from $84.84M to $137.23M, and the quick ratio increased from 10.06 to 13.59.
D
Sell
1/11/2018Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 1/11/2018 due to a large decline in the total return index and volatility index.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 1/11/2018 due to a large decline in the total return index and volatility index.
D
Sell
11/3/2017Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 11/3/2017 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.7334 to -$0.6203, EBIT increased 14.7% from -$15.17M to -$12.94M, and operating cash flow increased 8% from -$11.71M to -$10.77M.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 11/3/2017 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.7334 to -$0.6203, EBIT increased 14.7% from -$15.17M to -$12.94M, and operating cash flow increased 8% from -$11.71M to -$10.77M.
D
Sell
5/23/2017Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 5/23/2017 due to a large decline in the volatility index, total return index and efficiency index. Net income declined 44.65% from -$11.09M to -$16.04M, and total capital declined 10.98% from $132.8M to $118.23M.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to D- from D on 5/23/2017 due to a large decline in the volatility index, total return index and efficiency index. Net income declined 44.65% from -$11.09M to -$16.04M, and total capital declined 10.98% from $132.8M to $118.23M.
D
Sell
4/3/2017Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 04/03/2017.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D from D- on 04/03/2017.
D
Sell
12/1/2016Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 12/1/2016 due to a noticeable increase in the efficiency index, total return index and volatility index.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to D- from E+ on 12/1/2016 due to a noticeable increase in the efficiency index, total return index and volatility index.
E
Sell
9/1/2016Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to E+ from E on 9/1/2016 due to an increase in the volatility index and total return index.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to E+ from E on 9/1/2016 due to an increase in the volatility index and total return index.
E
Sell
8/5/2016Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to E from E- on 8/5/2016 due to a substantial increase in the growth index, volatility index and total return index. Earnings per share increased from -$5.3946 to -$0.4331.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to E from E- on 8/5/2016 due to a substantial increase in the growth index, volatility index and total return index. Earnings per share increased from -$5.3946 to -$0.4331.
E
Sell
7/28/2016Downgrade
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E- from E on 7/28/2016 due to a decline in the volatility index.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E- from E on 7/28/2016 due to a decline in the volatility index.
E
Sell
6/20/2016Upgraded
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to E from E- on 6/20/2016 due to an increase in the volatility index.
Corvus Pharmaceuticals, Inc. (CRVS) was upgraded to E from E- on 6/20/2016 due to an increase in the volatility index.
E
Sell
6/16/2016None
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E- from U on 06/16/2016.
Corvus Pharmaceuticals, Inc. (CRVS) was downgraded to E- from U on 06/16/2016.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
